Molecular Pathways and Targeted Therapy in Cholangiocarcinoma

被引：2

作者：

Dabney, Raetasha S. ^{[1
]}

Khalife, Mustapha ^{[1
]}

Shahid, Kamran ^{[1
]}

Phan, Alexandria T. ^{[1
]}

机构：

[1] Univ Texas Tyler, Hlth Sci Ctr Tyler, UT Hlth North Campus Tyler, Div Hematol & Oncol, Tyler, TX 75708 USA

来源：

CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2019年 / 17卷 / 11期

关键词：

Biliary tract cancer; cholangiocarcinoma (CCA); fibroblast growth factor receptor (FGFR); gene mutations; molecular pathways; targeted therapy; MEK INHIBITOR TRAMETINIB; DOSE-ESCALATION; PHASE-I; GROWTH; HSP90; CANCER; FGFR3; TRANSLOCATIONS; SENSITIVITY; FUSIONS;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Cholangiocarcinoma (CCA) encompasses a rare group of malignancies arising from epithelial cells lining the biliary tree that connects the liver and gallbladder to the small intestine. Most patients present with advanced incurable disease that has a poor prognosis, and standard treatment options remain limited. Effective nontoxic treatment options for advanced CCA are needed. Fibroblast growth factors (FGFs) and their fibroblast growth factor receptor (FGFR) pathways are crucial to cellular proliferation, cellular survival, and differentiation of many malignancies, but are especially relevant in CCA. The targeting of FGF/FGFR has become the most promising approach to treating patients with advanced/metastatic CCA. Here we review CCA, and discuss the promise of FGFR-directed therapy in advanced CCA.

引用

页码：630 / 637

页数：8

共 48 条

[1] FGFR3 Translocations in Bladder Cancer: Differential Sensitivity to HSP90 Inhibition Based on Drug Metabolism [J].

Acquaviva, Jaime ;

He, Suqin ;

Zhang, Chaohua ;

Jimenez, John-Paul ;

Nagai, Masazumi ;

Sang, Jim ;

Sequeira, Manuel ;

Smith, Donald L. ;

Ogawa, Luisa Shin ;

Inoue, Takayo ;

Tatsuta, Noriaki ;

Knowles, Margaret A. ;

Bates, Richard C. ;

Proia, David A. .

MOLECULAR CANCER RESEARCH, 2014, 12 (07) :1042-1054

[2]

[Anonymous], J CLIN ONCOL S

[3] Fibroblast Growth Factor Receptor 2 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Cholangiocarcinoma [J].

Arai, Yasuhito ;

Totoki, Yasushi ;

Hosoda, Fumie ;

Shirota, Tomoki ;

Hama, Natsuko ;

Nakamura, Hiromi ;

Ojima, Hidenori ;

Furuta, Koh ;

Shimada, Kazuaki ;

Okusaka, Takuji ;

Kosuge, Tomoo ;

Shibata, Tatsuhiro .

HEPATOLOGY, 2014, 59 (04) :1427-1434

[4]

Bellovin DI, 2014, CANC RES S, V74

[5] Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma [J].

Borad, Mitesh J. ;

Gores, Gregory J. ;

Roberts, Lewis R. .

CURRENT OPINION IN GASTROENTEROLOGY, 2015, 31 (03) :264-268

[6] Integrated Genomic Characterization Reveals Novel, Therapeutically Relevant Drug Targets in FGFR and EGFR Pathways in Sporadic Intrahepatic Cholangiocarcinoma [J].

Borad, Mitesh J. ;

Champion, Mia D. ;

Egan, Jan B. ;

Liang, Winnie S. ;

Fonseca, Rafael ;

Bryce, Alan H. ;

McCullough, Ann E. ;

Barrett, Michael T. ;

Hunt, Katherine ;

Patel, Maitray D. ;

Young, Scott W. ;

Collins, Joseph M. ;

Silva, Alvin C. ;

Condjella, Rachel M. ;

Block, Matthew ;

McWilliams, Robert R. ;

Lazaridis, Konstantinos N. ;

Klee, Eric W. ;

Bible, Keith C. ;

Harris, Pamela ;

Oliver, Gavin R. ;

Bhavsar, Jaysheel D. ;

Nair, Asha A. ;

Middha, Sumit ;

Asmann, Yan ;

Kocher, Jean-Pierre ;

Schahl, Kimberly ;

Kipp, Benjamin R. ;

Fritcher, Emily G. Barr ;

Baker, Angela ;

Aldrich, Jessica ;

Kurdoglu, Ahmet ;

Izatt, Tyler ;

Christoforides, Alexis ;

Cherni, Irene ;

Nasser, Sara ;

Reiman, Rebecca ;

Phillips, Lori ;

McDonald, Jackie ;

Adkins, Jonathan ;

Mastrian, Stephen D. ;

Placek, Pamela ;

Watanabe, Aprill T. ;

LoBello, Janine ;

Han, Haiyong ;

Von Hoff, Daniel ;

Craig, David W. ;

Stewart, A. Keith ;

Carpten, John D. .

PLOS GENETICS, 2014, 10 (02)

[7] Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application [J].

Chae, Young Kwang ;

Ranganath, Keerthi ;

Hammerman, Peter S. ;

Vaklavas, Christos ;

Mohindra, Nisha ;

Kalyan, Aparna ;

Matsangou, Maria ;

Costa, Ricardo ;

Carneiro, Benedito ;

Villaflor, Victoria M. ;

Cristofanilli, Massimo ;

Giles, Francis J. .

ONCOTARGET, 2017, 8 (09) :16052-16074

[8] Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance [J].

Chell, V. ;

Balmanno, K. ;

Little, A. S. ;

Wilson, M. ;

Andrews, S. ;

Blockley, L. ;

Hampson, M. ;

Gavine, P. R. ;

Cook, S. J. .

ONCOGENE, 2013, 32 (25) :3059-3070

[9]

Chen YY, 2018, ANN ONCOL S, V29

[10]

DELEON T, 2018, J CLIN ONCOL S, V36

← 1 2 3 4 5 →